RFK Jr. wants Americans to use peptides that were banned over safety risks
The FDA is reportedly planning to allow production of 14 previously banned peptides.
Signal weather
Stable
The story has moved beyond the first headline and now acts as a reliable context anchor.
Anti-vaccine Health Secretary Robert F. Kennedy Jr.—who has long dismissed reams of data on lifesaving vaccines as being insufficient to prove safety—is pushing the Food and Drug Administration to lift restrictions on over a dozen injectable peptide treatments. The treatments have little to no efficacy data behind them and were previously banned by the FDA for posing significant safety risks. Kennedy is a self-proclaimed "big fan" of the risky treatments. Peptides, generally, are chains of amino acids linked together with peptide bonds, a link between the carboxyl group of one amino acid and the amino group of another. Bioactive peptides can have a range of cellular functions and influence various biochemical processes. Well-established, FDA-approved types of peptide drugs include GLP-1s for obesity and insulin for diabetes. But online, peptide drugs are now seemingly synonymous with unproven, non-FDA-approved treatment. They've grown extremely popular among wellness influencers, celebrities, and "biohackers," who claim without evidence that peptides can treat various diseases, reverse aging, and improve appearance. On February 27, Kennedy touted such unproven peptides as a guest on Joe Rogan's podcast, saying he had used them to treat injuries with "really good effect." He also vowed to end the FDA's "war on peptides" and revealed his plan to reverse the FDA's restrictions on many of them. Read full article Comments
Stay on the signal
Follow RFK Jr. wants Americans to use peptides that were banned over safety risks
Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.
Story map
Understand this topic fast
A quick entry into the story: why it matters now, who is involved, and where to go next for context.
Why it matters now
Topic constellation
Open the live map for this story
See which entities, story threads, sources, and follow-up articles shape this story right now.
Click nodes to continue
Entity pages
Story timeline
Continue with this story
A short sequence of events and follow-up stories to understand the arc quickly.
How reliable this looks
Signal and trust for Ars Technica
This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.
Reliability
92
Freshness
100
Sources in storyline
1
Related articles
More stories that share tags, source, or category context.
A revolutionary cancer treatment could transform autoimmune disease
Researchers are testing CAR T cell therapy as a way to reset the immune system.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
The US is betting on AI to catch insider trading in prediction markets
The Commodity Futures Trading Commission wants us to know it's taking this very seriously.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Russia pressures university students to become wartime drone pilots
Universities promise no frontline duty and perks if students enlist in military.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Anthropic’s $1.5B copyright settlement is getting messy as judge delays approval
Lawyers accused of rushing historic settlement to seize $320 million in fees.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
More from Ars Technica
Fresh reporting and follow-up coverage from the same newsroom.
A revolutionary cancer treatment could transform autoimmune disease
Researchers are testing CAR T cell therapy as a way to reset the immune system.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
The US is betting on AI to catch insider trading in prediction markets
The Commodity Futures Trading Commission wants us to know it's taking this very seriously.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Russia pressures university students to become wartime drone pilots
Universities promise no frontline duty and perks if students enlist in military.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Anthropic’s $1.5B copyright settlement is getting messy as judge delays approval
Lawyers accused of rushing historic settlement to seize $320 million in fees.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.